Galectin Therapeutics Inc Financials
This page shows Galectin Therapeutics Inc (GALT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Galectin remains a research-stage enterprise funding a cash-intensive development program with outside capital while liabilities accumulate faster than repair.
FY2025 looked better on the income statement because R&D spending fell to$14.3M from$36.6M in FY2024. But operating cash burn was still-$23.9M and total liabilities climbed to$145.7M , so the narrower loss reflects lower spending intensity rather than a business that has started to internally fund itself.
Cash conversion is unusually clean: with little sign of non-cash cushioning, operating cash burn has broadly tracked reported losses from FY2023 through FY2025. In FY2025, operating cash flow was
Liquidity and solvency diverged in FY2025 as the current ratio rebounded to 2.4x and cash reached
Financial Health Signals
Galectin Therapeutics Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Galectin Therapeutics Inc passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Galectin Therapeutics Inc reported a net loss of $30.8M while operations used $23.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Galectin Therapeutics Inc reported an operating loss of $20.1M against $7.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Galectin Therapeutics Inc reported -$30.8M in net income in fiscal year 2025. This represents an increase of 34.5% from the prior year.
Galectin Therapeutics Inc earned -$0.48 per diluted share (EPS) in fiscal year 2025. This represents an increase of 36.8% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Galectin Therapeutics Inc held $17.7M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
None of these metrics is reported for fiscal year 2025.
Capital Allocation
Galectin Therapeutics Inc invested $14.3M in research and development in fiscal year 2025. This represents a decrease of 60.9% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
GALT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $14.3M-60.9% | $36.6M+13.8% | $32.1M+1.2% | $31.7M+33.2% | $23.8M+32.5% | $18.0M+140.7% | $7.5M+15.4% | $6.5M-44.8% | $11.7M-23.5% | $15.3M+16.9% | $13.1M+55.7% | $8.4M+48.1% | $5.7M+25.6% | $4.5M+27.4% | $3.6M |
| SG&A Expenses | N/A | $5.8M-1.1% | $5.9M-1.3% | $5.9M-10.2% | $6.6M+4.0% | $6.4M+16.3% | $5.5M-8.4% | $6.0M-16.3% | $7.1M+57.6% | $4.5M-26.5% | $6.2M-11.6% | $7.0M-0.6% | $7.0M+9.2% | $6.4M+19.4% | $5.4M-21.7% | $6.9M |
| Operating Income | N/A | -$20.1M+52.7% | -$42.4M-11.5% | -$38.1M+0.7% | -$38.4M-27.1% | -$30.2M-28.7% | -$23.4M-74.5% | -$13.4M+1.2% | -$13.6M+16.3% | -$16.2M+24.4% | -$21.5M-7.0% | -$20.1M-30.1% | -$15.4M-27.5% | -$12.1M-22.3% | -$9.9M+4.9% | -$10.4M |
| Interest Expense | N/A | $7.3M+32.3% | $5.5M+98.4% | $2.8M+170.3% | $1.0M+111.2% | $489K+462.1% | $87K0.0% | $87K-74.1% | $336K+2700.0% | $12K | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$30.8M+34.5% | -$47.0M-14.6% | -$41.1M-5.9% | -$38.8M-27.0% | -$30.5M-30.1% | -$23.5M-76.5% | -$13.3M+4.4% | -$13.9M+14.4% | -$16.2M+24.3% | -$21.4M-7.0% | -$20.0M-26.8% | -$15.8M-30.6% | -$12.1M-24.9% | -$9.7M+11.4% | -$10.9M |
| EPS (Diluted) | — | -$0.48+36.8% | -$0.76-2.7% | -$0.74-13.8% | -$0.65-25.0% | -$0.52-26.8% | -$0.41 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
GALT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $19.5M+11.6% | $17.5M-38.0% | $28.2M+32.5% | $21.3M-49.1% | $41.8M+41.3% | $29.6M-38.9% | $48.5M+438.2% | $9.0M+116.4% | $4.2M-73.7% | $15.8M-40.2% | $26.4M-11.0% | $29.7M+177.0% | $10.7M+12.0% | $9.6M+44.6% | $6.6M |
| Current Assets | $19.4M+12.7% | $17.3M-37.7% | $27.7M+34.8% | $20.6M-50.9% | $41.8M+41.9% | $29.5M-38.9% | $48.2M+445.8% | $8.8M+131.3% | $3.8M-75.8% | $15.8M-40.2% | $26.4M-11.0% | $29.7M+177.5% | $10.7M+12.3% | $9.5M+46.4% | $6.5M |
| Cash & Equivalents | $17.7M+17.2% | $15.1M-41.1% | $25.7M+38.0% | $18.6M-53.1% | $39.6M+46.1% | $27.1M-42.8% | $47.5M+475.3% | $8.3M+170.3% | $3.1M-80.1% | $15.4M-40.6% | $25.8M-11.3% | $29.1M+177.7% | $10.5M+12.0% | $9.4M+46.4% | $6.4M |
| Total Liabilities | $145.7M+20.9% | $120.6M+36.3% | $88.4M+65.4% | $53.5M+36.4% | $39.2M+625.2% | $5.4M+88.3% | $2.9M+36.2% | $2.1M-55.1% | $4.7M+24.1% | $3.8M-54.8% | $8.4M-1.3% | $8.5M-8.1% | $9.2M+10.0% | $8.4M-3.9% | $8.7M |
| Current Liabilities | $8.0M-77.3% | $35.4M+125.9% | $15.7M+20.5% | $13.0M+44.0% | $9.0M+67.3% | $5.4M+91.5% | $2.8M+33.8% | $2.1M-29.0% | $3.0M-21.5% | $3.8M+177.9% | $1.4M-20.1% | $1.7M-31.5% | $2.5M+51.8% | $1.6M-26.0% | $2.2M |
| Total Equity | -$127.9M-22.1% | -$104.8M-69.1% | -$62.0M-82.7% | -$33.9M-3898.1% | $893K-96.0% | $22.5M-48.8% | $43.9M+747.8% | $5.2M+1076.4% | -$530K-105.1% | $10.3M-42.9% | $18.0M-14.9% | $21.2M+1331.1% | $1.5M+27.1% | $1.2M+154.8% | -$2.1M |
| Retained Earnings | -$432.5M-7.7% | -$401.6M-13.3% | -$354.4M-14.5% | -$309.6M-14.4% | -$270.7M-12.8% | -$240.0M-10.9% | -$216.4M-10.3% | -$196.2M-8.3% | -$181.2M-10.7% | -$163.7M-16.9% | -$140.0M-17.8% | -$118.9M-16.6% | -$102.0M | N/A | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
GALT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$15.9M | -$23.9M+42.8% | -$41.8M-26.7% | -$33.0M-6.1% | -$31.1M-27.8% | -$24.3M-18.0% | -$20.6M-89.9% | -$10.8M-6.6% | -$10.2M+35.9% | -$15.9M+3.2% | -$16.4M+3.4% | -$17.0M-36.7% | -$12.4M-66.0% | -$7.5M+0.2% | -$7.5M-32.1% | -$5.7M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0 | $0-100.0% | $5K0.0% | $5K |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$17.0M-36.7% | -$12.4M-66.0% | -$7.5M+0.3% | -$7.5M-32.1% | -$5.7M |
| Investing Cash Flow | N/A | $0 | $0 | $0 | $0 | $0 | $0 | N/A | $0 | $0 | N/A | N/A | N/A | N/A | $64K+526.7% | -$15K |
| Financing Cash Flow | $15.4M | $26.5M-15.2% | $31.2M-22.0% | $40.0M+300.3% | $10.0M-72.8% | $36.8M+13897.7% | $263K-99.5% | $50.1M+225.6% | $15.4M+329.2% | $3.6M | N/A | N/A | N/A | $8.6M-17.2% | $10.4M+67.9% | $6.2M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
GALT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity | N/A | N/A | N/A | N/A | -3418.5%-3314.1pp | -104.4%-74.1pp | -30.3%+238.3pp | -268.6% | N/A | -208.3%-97.3pp | -111.0%-36.5pp | -74.5%+741.7pp | -816.2%+14.3pp | -830.5% | N/A |
| Return on Assets | -157.9%+111.1pp | -268.9%-123.3pp | -145.6%+36.6pp | -182.2%-109.2pp | -73.0%+6.3pp | -79.3%-51.8pp | -27.4%+126.9pp | -154.3%+235.8pp | -390.2%-254.5pp | -135.7%-59.9pp | -75.8%-22.6pp | -53.2%+59.6pp | -112.8%-11.6pp | -101.2%+63.9pp | -165.1% |
| Current Ratio | 2.42+1.9x | 0.49-1.3x | 1.77+0.2x | 1.58-3.1x | 4.63-0.8x | 5.46-11.6x | 17.10+12.9x | 4.19+2.9x | 1.29-2.9x | 4.18-15.2x | 19.41+2.0x | 17.42+13.1x | 4.30-1.5x | 5.81+2.9x | 2.94 |
| Debt-to-Equity | N/A | N/A | N/A | N/A | 43.91+43.7x | 0.24+0.2x | 0.07-0.3x | 0.41 | N/A | 0.37-0.1x | 0.46+0.1x | 0.40-5.8x | 6.23-1.0x | 7.21 | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$127.9M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Where Galectin Therapeutics Inc Ranks
Frequently Asked Questions
Is Galectin Therapeutics Inc profitable?
No, Galectin Therapeutics Inc (GALT) reported a net income of -$30.8M in fiscal year 2025.
What is Galectin Therapeutics Inc's operating cash flow?
Galectin Therapeutics Inc (GALT) recorded an outflow of $23.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Galectin Therapeutics Inc's total assets?
Galectin Therapeutics Inc (GALT) had $19.5M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Galectin Therapeutics Inc spend on research and development?
Galectin Therapeutics Inc (GALT) invested $14.3M in research and development during fiscal year 2025.
What is Galectin Therapeutics Inc's current ratio?
Galectin Therapeutics Inc (GALT) had a current ratio of 2.42 as of fiscal year 2025, which is generally considered healthy.
What is Galectin Therapeutics Inc's return on assets (ROA)?
Galectin Therapeutics Inc (GALT) had a return on assets of -157.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Galectin Therapeutics Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Galectin Therapeutics Inc (GALT) held $17.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $23.9M over that year. Dividing the one by the other, the reported balance equals about 9 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Galectin Therapeutics Inc's debt-to-equity ratio negative or not reported?
Galectin Therapeutics Inc (GALT) has negative shareholder equity of -$127.9M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Galectin Therapeutics Inc's Piotroski F-Score?
Galectin Therapeutics Inc (GALT) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Galectin Therapeutics Inc's earnings high quality?
Galectin Therapeutics Inc (GALT) reported a net loss of $30.8M while operations used $23.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Galectin Therapeutics Inc cover its interest payments?
Galectin Therapeutics Inc (GALT) reported an operating loss of $20.1M against $7.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.